**Appendix**

**Dosing of 3 Targeted Agents in Novel Drug Combinations Used at the Precision Medicine Clinic of the University of California San Diego**

Mina Nikanjam, MD, PhD; Jose Tinajero, PharmD; Mary McGann, PharmD, BCOP; Jerry Li, PharmD; Jincheng Yang, PharmD; Felicity Shen, PharmD; Jason K. Sicklick, MD; Shumei Kato, MD; Edmund Capparelli, PharmD; Razelle Kurzrock, MD

This Appendix has not been edited and is provided as supplemental materials for this article, which was published in the *Journal of Hematology Oncology Pharmacy* in February 2023.

**Supplemental Figure 1:** Class of anti-cancer therapy administered in combination with drugs of interest. Safe and tolerable dose was one that was tolerated for at least one month with no clinically significant serious toxicities. Trametinib: A. Safe and Tolerable Dose or No Safe and Tolerable Dose, Everolimus: B. Safe and Tolerable Dose or No Safe or Tolerable Dose, Palbociclib: C. Safe and Tolerable Dose or No Safe or Tolerable Dose

**Supplemental** **Figure 1A:**

■ =Targeted ■ =Immunotherapy + Targeted

■ =Chemotherapy + Targeted ■ =Chemotherapy + Immunotherapy + Targeted

■ =Hormonal + Targeted ■ =Hormonal + Immunotherapy + Therapy

■ =Hormonal ■ =Chemotherapy + Hormonal + Immunotherapy + Targeted

■ =Immunotherapy ■ =Chemotherapy

**Supplemental Figure 1B:**

■ =Targeted ■ =Immunotherapy + Targeted

■ =Chemotherapy + Targeted ■ =Chemotherapy + Immunotherapy + Targeted

■ =Hormonal + Targeted ■ =Hormonal + Immunotherapy + Therapy

■ =Hormonal ■ =Chemotherapy + Hormonal + Immunotherapy + Targeted

■ =Immunotherapy ■ =Chemotherapy

**Supplemental Figure 1C**

■ =Targeted ■ =Immunotherapy + Targeted

■ =Chemotherapy + Targeted ■ =Chemotherapy + Immunotherapy + Targeted

■ =Hormonal + Targeted ■ =Hormonal + Immunotherapy + Therapy

■ =Hormonal ■ =Chemotherapy + Hormonal + Immunotherapy + Targeted

■ =Immunotherapy ■ =Chemotherapy

**Figure 1F**

**Supplemental Figure 2.** Number of drugs given in combination (including drug of interest): A. Trametinib, B. Everolimus, C. Palbociclib



**Supplemental Figure 2A**



**Supplemental Figure 2B**



**Supplemental Figure 2C**

**Supplemental Table 1. Anti-Cancer Drugs used in Combination with Trametinib**

|  |
| --- |
| Anti-Cancer Drugs (N=105) |
| Immune checkpoint inhibitors, N (%) Pembrolizumab (Anti-PD1) Nivolumab (Anti-PD1) Ipilimumab (Anti-CTLA4) | 30 (28)16131 |
| Targeted therapy, N(%) Bevacizumab (Anti-VEGF) Palbociclib (CDK 4/6 Inhibitor) Afatinib (EGFR Inhibitor) Lenvatinib (VEGFR Inhibitor) Erlotinib (EGFR Inhibitor) Lapatinib (HER2/EGFR Inhibitor) Pazopanib (VEGFR Inhibitor) Sorafenib (BRAF/VEGFR Inhibitor) Cetuximab (Anti-EGFR) Everolimus (mTOR Inhibitor) Panitumumab (Anti-EGFR) Ruxolitinib (JAK Inhibitor) Tamoxifen (SERM) Cabozantinib (TKI Inhibitor) Ixazomib (Proteasome Inhibitor) | 61 (58)13126433323221111 |
|  Chemotherapy, N(%) Carboplatin (Platinum Agent) Etoposide (Topoisomerase Inhibitor) FOLFIRI\* Cisplatin (Platinum Agent) Irinotecan (Topoisomerase Inhibitor) | 6 (6)21111 |
| Miscellaneous, N(%) Sulindac (NSAID) Metformin (Anti-Hyperglycemic) | 8 (7)71 |
|  Hormonal Therapy, N(%) Letrozole (Aromatase Inhibitor) | 1 (1)1 |

\*Drugs included in FOLFIRI are (Leucovorin, 5-Fluorouracil, Irinotecan)

**Supplemental Table 2. Anti-Cancer Drugs used in Combination with Everolimus**

|  |
| --- |
| Anti-Cancer Drugs (N=71) |
| Immune checkpoint inhibitors, N(%) Pembrolizumab (Anti-PD1) | 2 (3)2 |
| Targeted Therapy, N(%) Lenvatinib (VEGFR Inhibitor) Trastuzumab (Anti-HER2) Bevacizumab (Anti-VEGF) Lapatinib (HER2/EGFR Inhibitor) Pazopanib (VEGFR Inhibitor) Palbociclib (CDK 4/6 Inhibitor) Abemaciclib (CDK 4/6 Inhibitor) Erlotinib (EGFR Inhibitor) Trametinib (MEK Inhibitor) Cabozantinib (TKI Inhibitor) Vismodegib (Hedgehog Inhibitor) Copanlisib (PI3K Inhibitor) Olaparib (PARP Inhibitor) | 41 (58)8844332222111 |
| Chemotherapy, N(%) Carboplatin (Platinum Agent) Capecitabine (Pyrimidine Analog) Vinorelbine (Vinca Alkaloid) Etoposide PO (Topoisomerase Inhibitor) Gemcitabine (Pyrimidine Analog) Irinotecan (Topoisomerase Inhibitor) Oxaliplatin (Platinum Agent) Paclitaxel (Taxane) | 17 (24)82211111 |
| Hormonal Therapy, N(%) Exemestane (Aromatase Inhibitor) Enzalutamide (Anti-Androgen) Letrozole (Aromatase Inhibitor) | 8 (11)422 |
| Miscellaneous, N(%) Sulindac (NSAID) Metformin (Anti-Hyperglycemic) | 3 (4)21 |

**Supplemental Table 3. Anti-Cancer Drugs used in Combination with Palbociclib**

|  |
| --- |
| Anti-Cancer Drugs (N=66) |
| Immune checkpoint inhibitors, N(%) Nivolumab (Anti-PD1) Pembrolizumab (Anti-PD1) | 10 (15)73 |
| Targeted Therapy Trametinib (MEK Inhibitor) Bevacizumab (Anti-VEGF) Lenvatinib (VEGFR Inhibitor) Cetuximab (Anti-EGFR) Anakinra (IL-1 Inhibitor) Everolimus (mTOR Inhibitor) Afatinib (EGFR Inhibitor) Dabrafenib (BRAF Inhibitor) Ibrutinib (BTK Inhibitor) Lapatinib (HER2/EGFR Inhibitor) Olaparib (PARP Inhibitor) Osimertinib (EGFR Inhibitor) Ramucirumab (VEGF Inhibitor) Temsirolimus (mTOR Inhibitor) Trastuzumab (Anti-HER2) | 49 (74)1677432111111111 |
| Hormonal Therapy, N(%) Anastrazole (Aromatase Inhibitor) | 1 (2)1 |
| Miscellaneous, N(%) Sulindac (NSAID) Celecoxib (COX-2 Inhibitor) Metformin (Anti-Hyperglycemic) Nelfinavir (HIV Protease Inhibitor) | 6 (9)4111 |